Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PTC Therapeutics goes public on second try with $134mm IPO

Executive Summary

Just over three months after completing a $60mm Series G financing, PTC Therapeutics Inc. (focused on orphan and ultra-orphan diseases) has netted $134mm through its initial public offering of 9.6mm common shares (including the overallotment) at $15. Just days ago the company said it intended to sell 6.9mm shares between $13-16. This was PTC's second try after withdrawing an S-1 filing in 2007 because it already had sufficient funding through grants and licensing deals.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Technologies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies